Get started
Author

Masafumi Endo

Observed name: M Endo
ORCID: 0000-0003-3289-0127
Observed ORCID: 0000-0003-3289-0127
OpenAlex ID: A5102729041
Effects of Immunization with CCR5-Based Cycloimmunogen on Simian/HIVSF162P3 Challenge
2006 · Shogo Misumi, Daisuke Nakayama, et al. · The Journal of Immunology · 33
A Novel Cyclic Peptide Immunization Strategy for Preventing HIV-1/AIDS Infection and Progression
2003 · Shogo Misumi, Masafumi Endo, et al. · Journal of Biological Chemistry · 24
Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza
2019 · Toshiki Sekiya, Edin J Mifsud, et al. · Vaccine · 21
PDF
Human Immunodeficiency Virus-Induced Apoptosis of Human Breast Cancer Cells Via CXCR4 is Mediated by the Viral Envelope Protein But Does Not Require CD4
2008 · Shogo Misumi, Masafumi Endo, et al. · Current HIV Research · 19
Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells
2021 · Masashi Shingai, Naoki Nomura, et al. · Vaccine · 14
PDF
Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques
2022 · Brendon Y. Chua, Toshiki Sekiya, et al. · PLoS Pathogens · 9
PDF
Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine
2024 · Chimuka Handabile, Marumi Ohno, et al. · Scientific Reports · 8
PDF
Immune profiling of influenza‐specific B‐ and T‐cell responses in macaques using flow cytometry‐based assays
2020 · Marios Koutsakos, Toshiki Sekiya, et al. · Immunology and Cell Biology · 8
PDF
Clinical phase II and III studies of an AS03‐adjuvanted H5N1 influenza vaccine produced in an EB66® cell culture platform
2020 · Masafumi Endo, Mitsuyoshi Tanishima, et al. · Influenza and Other Respiratory Viruses · 8
PDF
Evidence as a HIV-1 Self-Defense Vaccine of Cyclic Chimeric Dodecapeptide Warped from Undecapeptidyl Arch of Extracellular Loop 2 in Both CCR5 and CXCR4
2001 · Shogo Misumi, Nobutoki Takamune, et al. · Biochemical and Biophysical Research Communications · 8
Epitope analysis of the cerebrospinal fluid IgG in HTLV-I associated myelopathy patients using phage display method
2004 · J Fujimori, I Nakashima, et al. · Journal of Neuroimmunology · 7
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult and elderly subjects: a randomized, double-blind, placebo-controlled, phase 1/2 clinical study in Japan
2022 · Mitsuyoshi Tanishima, Kayo Ibaraki, et al. · medRxiv · 5
PDF
Treatment of Breast Cancer Cells with Proteasome Inhibitor Lactacystin Increases the Level of Sensitivity to Cell Death Induced by Human Immunodeficiency Virus Type 1
2010 · Masafumi Endo, Shouichirou Gejima, et al. · Biological and Pharmaceutical Bulletin · 4
PDF
An XBB.1.5-based inactivated SARS-CoV-2 vaccine partially protects against XBB.1.5 and JN.1 strains in hamsters
2025 · Ryuta Uraki, Mutsumi Ito, et al. · npj Viruses · 3
PDF
Assessing the pyrogenicity of whole influenza virus particle vaccine in cynomolgus macaques
2022 · Marumi Ohno, Masataka Sagata, et al. · Vaccine · 3
PDF
Preliminary report: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, KD-414, in healthy adult participants: a non-randomized, open-label phase 2/3 clinical study in Japan
2022 · Keishi Kido, Kayo Ibaragi, et al. · medRxiv
PDF
Works count: 16
Citation count: 174
H-index: 8
I10-index: 5
Year
Topic
Type